Sweden-based Medivir announced on 25 August 2011 that its subsidiary BioPhausia had reached an agreement to sell its generics business (BMM Pharma) to Bluefish Pharmaceuticals (Bluefish) for SEK 26 million plus the value of inventories, some SEK 12 million. The staff of BMM Pharma will not be transferred in the acquisition.
Medivir subsidiary BioPhausia sells generics business
Home/Pharma News
|
Posted 02/09/2011
0
Post your comment

CEO of BioPhausia Mr Maris Hartmanis commented that ‘this deal is a natural last step in the concentration and focus of BioPhausia’s business, which began about a year ago. We will now be focusing on the ongoing commercial development of our Proprietary Products and Parallel Imported Products’.
Bluefish announced that this acquisition was strategically important to its continued expansion and will allow it to enhance the value of its existing product portfolio by adding generic pharmaceuticals within the niche segment. The portfolio acquired includes 19 pharmaceutical products, of which most are used in pain, inflammation and gastrointestinal therapy.
Following the acquisition, Bluefish, which was founded in 2005, now has 68 products in its portfolio, of which 41 have already been launched, bringing it closer to its goal of 100 products. The extra products are expected to increase net sales for Bluefish by around SEK 30 million on an annual basis.
CEO and founder of Bluefish Mr Karl Karlsson added that ‘Bluefish is the fastest growing generic pharmaceutical company in the Nordic region. Our scale, together with our broad presence throughout the rest of Europe, offers new pan-European business opportunities’.
Source: Bluefish, Medivir
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News Posted 15/01/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment